L'Agenzia Italiana del Farmaco rende disponibili nuove e importanti
informazioni sul rischio cardiovascolare di aceclofenac simile a quello di diclofenac e degli inibitori selettivi della COX-2.
Potential risk of medication error or delay in therapy for patients that require high concentration potassium chloride.
Il Comitato di Valutazione del Rischio per la Farmacovigilanza
(Pharmacovigilance Risk Assessment Committee, PRAC) ha concluso la
valutazione periodica del rischio/beneficio di Valdoxan/Thymanax
(agomelatina) e ha raccomandato ulteriori misure di minimizzazione del
rischio di effetti collaterali epatici gravi.
Risk of injected particulate material which may result in local inflammation, phlebitis, and/or low-level allergic response.
In FOCUS March 2013, Antonio Addis discusses the inadequacies of information and communication in pharmacovigilance and also challenges us, ‘Do try and find someone asserting that information in pharmacovigilance is useless’. In FOCUS July 2013, Richard Smith talks about peoples’ perception of drug safety and ends, ‘My conclusion is that Britain—like most countries—is awash with drugs, and that although Britons are well aware that some drugs can be dangerous they are generally hazy on the ratio of benefits to risks.
Cobalamine or vitamin B12 is a hydrosoluble vitamin, essential in the process of DNA synthesis, haematopoiesis and neuronal cell proliferation and maturation. Vitamin B12 deficiency is a relatively common condition, especially in elderly population, and is associated with potentially severe haematological and neurological complications, especially when it is not diagnosed in the initial phase of symptoms appearance.1
It was recently published in the International Journal of Ophthalmology a systematic review of the literature that compares the efficacy and safety of bevacizumab and ranibizumab in the treatment of age-related macular degeneration (AMD). Zhang and his colleagues collected data from 4 randomized clinical trials (RCTs) and 11 observational studies, for a total number of more than 4,000 patients. They concluded that the effectiveness of treatments is similar, but that ranibizumab is safer than bevacizumab .
A well-known mechanism
80.211.154.110
